Omid Farokhzad: From Tehran to the Edge of Nanomedicine

After nearly two decades at Harvard, he made the pivotal decision in 2022 to step away from academic life and devote himself fully to entrepreneurship. This move reflected his belief that some of the most transformative advances in medicine require the rapid development and scaling that startups can offer. He began leading two major biotechnology companies—SEER and PrognomiQ—each focused on advancing proteomics and molecular profiling.